id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-D-1261-0004,FDA,FDA-2022-D-1261,"Clostridioides Difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, or Prevention; Guidance for Industry",Other,Guidance,2026-05-11T04:00:00Z,2026,5,2026-05-11T04:00:00Z,,2026-05-11T17:45:41Z,,1,0,09000064b92cf3fb
FDA-2022-D-1261-0003,FDA,FDA-2022-D-1261,"Clostridioides Difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, or Prevention; Guidance for Industry; Availability",Notice,Notice of Availability,2026-05-11T04:00:00Z,2026,5,2026-05-11T04:00:00Z,,2026-05-11T17:42:11Z,2026-09267,0,0,09000064b92cf922
FDA-2022-D-1261-0002,FDA,FDA-2022-D-1261,"Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention Guidance for Industry DRAFT GUIDANCE",Other,Guidance,2022-10-28T04:00:00Z,2022,10,2022-10-28T04:00:00Z,2022-12-28T04:59:59Z,2024-11-07T00:43:55Z,,1,0,090000648546a099
FDA-2022-D-1261-0001,FDA,FDA-2022-D-1261,"Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2022-10-28T04:00:00Z,2022,10,2022-10-28T04:00:00Z,,2022-10-28T19:26:54Z,2022-23457,0,0,090000648546a16a